Topical bacteriocin therapy with epidermicin NI01 for dermatological infections (TOBRADERM)

使用表皮霉素 NI01 局部细菌素治疗皮肤感染 (TOBRADERM)

• 批准号: 10071961
• 金额: $ 89.04万
• 依托单位: AMPROLOGIX LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2024
• 资助国家: 英国
• 起止时间: 2024 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10071961
• 关键词: Topical; bacteriocin; therapy; epidermicin; NI01

Amprologix is a company developing novel antibiotics to meet the global threat of antimicrobial resistance (AMR). AMR happens when bacteria become resistant to antibiotics and results in treatment failure and increased death from 'drug resistant' infections. These infections killed over 1.2 million people in 2019 and new antibiotics are urgently needed. If we don't develop new antibiotics, our current medical system may fail and things like cancer therapy and routine surgery may result in a fatal infection.In this TOBRADERM project, Amprologix will test a new antibiotic compound, epidermicin NI01, for treating skin infections, which affect millions of people every year in the UK and are the cause of more than 10% of all antibiotic prescriptions. Skin infections can be minor but can also result in severe and fatal outcomes, and they are increasingly complicated by AMR. We will develop epidermicin to be used externally (topical application), being applied directly to infected areas. This increases the killing action but also helps preserve current antibiotics, taken orally or by injection, for use against serious infections, like those in the blood.Epidermicin NI01 is from a new class of antibiotic compound, the bacteriocins (small protein-like molecules). Whilst bacteriocins are not used to treat patients yet, epidermicin has many features that increase the chance of it being a successful drug. These features include properties that minimise any risks that have stopped development of previous bacteriocins: it has very potent activity against globally leading pathogens ('superbugs'), including those that are resistant to current antibiotics and the leading causes of skin infections; toxicity is extremely low, even in recent safety tests in animals; resistance is very unlikely to occur due to the novel way it kills target bacteria; and we have developed an extremely low-cost production system. Epidermicin will also not kill all kinds of bacteria meaning it will target the main pathogens, leaving other skin bacteria unharmed, protecting the 'microbiome'.Epidermicin is an extremely promising new antibiotic and success in the TOBRADERM project will allow Amprologix to access new drug markets, helping it grow into a global leader in 'topical therapeutics'. This will create jobs, generate income for the company and enable development of a new drug to treat skin infections, potentially benefitting over 1 million people a year in the UK.

Amprologix 是一家开发新型抗生素的公司，旨在应对全球抗菌素耐药性 (AMR) 的威胁。当细菌对抗生素产生耐药性并导致治疗失败并增加“耐药”感染导致的死亡时，就会发生抗菌素耐药性。 2019 年，这些感染导致超过 120 万人死亡，迫切需要新的抗生素。如果我们不开发新的抗生素，我们当前的医疗系统可能会失败，癌症治疗和常规手术等可能会导致致命的感染。在这个 TOBRADERM 项目中，Amprologix 将测试一种新的抗生素化合物表皮霉素 NI01，用于治疗皮肤感染，皮肤感染每年影响英国数百万人，占所有抗生素处方的 10% 以上。皮肤感染可能很轻微，但也可能导致严重和致命的后果，而且抗菌素耐药性使情况变得越来越复杂。我们将开发外用表皮霉素（局部应用），直接应用于感染部位。这增强了杀灭作用，但也有助于保留现有的口服或注射抗生素，用于对抗严重感染，如血液中的感染。Epidermicin NI01 来自一类新型抗生素化合物，即细菌素（类似蛋白质的小分子）。虽然细菌素尚未用于治疗患者，但表皮霉素具有许多特性，增加了其成为成功药物的机会。这些特性包括最大限度地减少先前细菌素开发停止的任何风险的特性：它对全球领先的病原体（“超级细菌”）具有非常有效的活性，包括那些对当前抗生素具有抗药性的病原体和皮肤感染的主要原因；即使在最近的动物安全测试中，毒性也极低；由于它杀死目标细菌的方式新颖，因此不太可能出现耐药性；我们开发了一种成本极低的生产系统。 Epidermicin 也不会杀死所有种类的细菌，这意味着它会针对主要病原体，而不会伤害其他皮肤细菌，从而保护“微生物群”。Epidermicin 是一种极具前景的新型抗生素，TOBRADERM 项目的成功将使 Amprologix 进入新药市场，帮助其成长为“局部治疗”的全球领导者。这将为公司创造就业机会、创造收入，并促进治疗皮肤感染的新药的开发，每年可能使超过 100 万人受益。